Annotation Detail
Information
- Associated Genes
- STK11
- Associated Variants
-
STK11 LOSS
(
ENST00000326873.12 )
STK11 LOSS ( ENST00000326873.12 ) - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- Preclinical study in 5 NSCLC cell lines. Two LKB1 (STK11) mutant cell lines had higher basal levels of mTOR activity (pS6K and p4EBP1 levels) but were not more sensitive to mTOR inhibitors (everolimus or rapamycin) than two wild type cell lines. Knockdown of LKB1 in one additional cell line did not lead to an increase in sensitivity to mTOR inhibitors.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1620
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5534
- Variant URL
- https://civic.genome.wustl.edu/links/variants/485
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Does Not Support
- Drug
- Sirolimus,Everolimus
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26027660
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Everolimus | Sensitivity | false |
| Sirolimus | Sensitivity | false |